Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Tianjin Jianli Technology R & D Co. Ltd. currently has 2 pending office actions in the Chemistry & Materials technology area. These actions are being reviewed by 2 distinct examiners, which introduces multiple perspectives into the prosecution of the company's chemical innovations. The involvement of 2 distinct art units further indicates that the pending applications are categorized into different technical specialties within the chemistry sector.
The workload is evenly split, with the busiest examiner, LEBLANC, KATHERINE DEGUIRE, managing 1 busiest examiner pending action. Since there are a matching number of distinct examiners for the 2 pending office actions, each examiner is responsible for an equal portion of the current pending volume. The presence of 2 distinct art units requires the company to adapt its strategy to the specific guidelines of different examination groups while addressing the individual styles of the assigned examiners. This distribution suggests a diverse range of technical challenges for the pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEBLANC, KATHERINE DEGUIRE | 1 | 34.6% | +36.0% |
| SHELTON, SYNPHANE LA'SHAWN | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18648449 | PROBIOTIC-CONTAINING SEA CUCUMBER PEPTIDE POWDER FOR IMPROVING IMMUNITY AND PREPARATION METHOD THEREOF | LEBLANC, KATHERINE DEGUIRE | — |
| 18647098 | PREPARATION METHOD AND USE OF YAK HIDE-DERIVED OLIGOPEPTIDE FERROUS CHELATE WITH HIGH ANTIOXIDANT ACTIVITY | SHELTON, SYNPHANE LA'SHAWN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18648449 | PROBIOTIC-CONTAINING SEA CUCUMBER PEPTIDE POWDER FOR IMPROVING IMMUNITY AND PREPARATION METHOD THEREOF | LEBLANC, KATHERINE DEGUIRE | — |
| Art Unit | Apps |
|---|---|
| 1791 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18648449 | PROBIOTIC-CONTAINING SEA CUCUMBER PEPTIDE POWDER FOR IMPROVING IMMUNITY AND PREPARATION METHOD THEREOF | LEBLANC, KATHERINE DEGUIRE | 1791 | §103§112 | Non-Final OA | — | Pending | Apr 28, 2024 |
| 18647098 | PREPARATION METHOD AND USE OF YAK HIDE-DERIVED OLIGOPEPTIDE FERROUS CHELATE WITH HIGH ANTIOXIDANT ACTIVITY | SHELTON, SYNPHANE LA'SHAWN | 1652 | §103§112Other | Non-Final OA | — | Pending | Apr 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTianjin Jianli Technology R & D Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Katherine Deguire Leblanc has the most, with 1 of Tianjin Jianli Technology R & D Co. Ltd.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
